1. Taiwan Stocks

  2. •

    Transportation

  3. •

    Other transportation
Vectorite Biomedical, Inc.

Vectorite Biomedical, Inc.

TTPEX:4170
12.00
TWD
+0.10
(+0.84%)
544.95MMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.44
2.41
0.74
0.89
3.58
4.9
0.63
0.51
0.41
0.98
1.28
1.32
1.4
- -
Basic EPS, GAAP
-1.01
0.81
-1.81
-2.02
-1.55
-0.72
-2.14
-1.42
0.12
-0.6
-0.15
-0.92
2.2
- -
Free Cash Flow per Basic Share
-1.98
-1.16
-5.38
-1.79
0.37
-3.01
-1.59
-1
-0.97
0.32
-0.08
-0.33
-0.22
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.15
11.99
10.52
8.8
8.58
7.96
6.78
6.03
6.47
6.11
9.83
8.89
11.07
11.67
Tangible Book Value per Share
10.15
11.99
10.52
8.8
8.56
7.33
6.38
5.5
6.15
5.8
9.34
8.75
11.06
11.66
Basic Weighted Avg Shares
28
39
40
39
40
42
42
48
70
44
44
44
44
44
Sales/Revenue/Turnover
41
93
30
35
144
206
27
25
29
43
56
58
61
- -
Operating Margin (%)
-81.01
-24.52
-236.29
-194.97
-37.37
-32.82
-310.18
-248.22
-147.4
-71.16
-28.88
-44.96
-35.68
- -
Depreciation Expense
4
4
6
8
8
13
20
19
17
9
9
9
8
- -
Net Income, GAAP
-28
31
-73
-80
-63
-30
-90
-68
8
-26
-7
-40
96
- -
Effective Tax Rate (%)
- -
15.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-69.97
33.83
-244.2
-228.35
-43.41
-14.7
-340.11
-277.75
29.05
-61.55
-11.82
-69.33
156.62
- -
Working Capital
351
428
184
140
147
72
96
84
234
217
210
194
176
171
LT Debt
- -
- -
27
- -
- -
- -
3
- -
- -
- -
- -
- -
- -
- -
Total Equity
380
485
423
357
381
337
340
345
467
441
431
390
485
511
Return on Invested Capital (%)
- -
-4.35
- -
- -
- -
- -
- -
- -
-10.45
- -
- -
- -
-5.01
- -
Return on Capital (%)
- -
7.96
- -
- -
- -
- -
- -
- -
2.07
- -
- -
- -
21.99
- -
Return on Common Equity (%)
-14.36
7.25
-16.08
-20.45
-17.46
-8.7
-29.07
-21.63
2.06
-5.82
-1.52
-9.77
22.01
- -

Capital Structure

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
44
Market Capitalization
527
613
545

Working Capital

TWD

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
205
192
190
Cash, Cash Equivalents & STI
177
171
166
Accounts Receivable, Net
9
3
5
Inventories
17
15
17
Total Current Liabilities
15
16
19
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
2.43%
8.48%
24.51%
Free Cash Flow
-113.99%
15.72%
-31.84%
Net Income, GAAP
-32.73%
-87.33%
-340.12%
Sales/Revenue/Turnover
38.48%
21.25%
6.29%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
58
2025
- -
- -
61
2026
- -
- -
- -

Semi-annual Earnings Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-0.92
2025
- -
- -
2.2
2026
- -
- -
- -

Semi-annual Dividends Per Share

TWD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Ming Chang Ou
Full Time Employees
43
Sector
Transportation
Industry
Other transportation
Address
No. 97, Xintai 5th Road New Taipei TP Taiwan 22175
IPO Date
Apr 15, 2013
Website
vectorite.com.tw
Similar Companies
Uber Technologies, Inc. (NYSE:UBER)
Adani Ports & Special Economic Zone Ltd (NSE:ADANIPORTS)
TAV Havalimanlari Holding A.S. (BIST:TAVHL)
Lyft, Inc. (NASDAQ:LYFT)
Wetour Robotics Limited (NASDAQ:WETO)
GMR Airports Ltd (NSE:GMRAIRPORT)
Business
Vectorite Biomedical Inc. Vectorite Biomedical Inc. (4170.TWO) is a Taiwan-based biotechnology company that engages in the research, development, and manufacturing of cell preparation products and provides commissioned production services for immune cell therapies. The company offers dendritic cell (DC) vaccines and natural killer (NK) cell preparations for cancer treatment; immune cell collection, processing, and storage services; cell preparation safety testing and anti-cancer immunity testing services; original design manufacturer (ODM) and contract development and manufacturing organization (CDMO) services; related medical consulting; and laboratory quality management services, with products primarily applied in infectious diseases, inflammation, cancer, and tumor treatments. Founded in 1993 and headquartered in New Taipei City, Taiwan, at No. 97, Xintai 5th Road, it operates mainly in the domestic Taiwanese market with limited international activities and focuses on adoptive cell therapy (ACT) technologies, including targeted immune effector cell transfer immunotherapy. Recent developments include collaboration with the Industrial Technology Research Institute (ITRI) announced in July 2025 to optimize immune cell expansion processes for infectious diseases and cancer treatments; expansion of hospital partnerships under Taiwan's special medical technology regulations, with 12 approved hospitals as of mid-2024 and plans to add 2 to 4 more in 2024; and positive clinical outcomes reported in 2024 from DC and NK cell therapies for late-stage cancers such as pancreatic, colorectal, and liver cancers, demonstrating extended median survival times.